What are the specific recommendations for the use of mivamutide injection for osteosarcoma?

Mifamurtide injection (Mifamurtide), also known asMepact, is an adjuvant immunotherapy drug used to treat non-metastaticosteosarcoma. Its active ingredientMTP-PE is a synthetic cell wall peptide that can activate monocytes and macrophages and improve the body's ability to recognize and eliminate tumor cells. The drug does not directly kill cancer cells, but delays or even prevents tumor recurrence by mobilizing the body's natural immune mechanism.

In international treatment protocols, mivamutide is recommended as an adjuvant drug after surgery and chemotherapy. The standard recommended dose is 2 mg/㎡ body surface area, administered through intravenous infusion, and each infusion needs to last 1 hour. The first 12 weeks are usually an intensive treatment period, with two injections per week, with at least three days between injections to avoid overstimulating the immune system. After that, it entered the maintenance period, which was changed to once a week for 24 weeks. The total treatment course was 36 weeks, with a total of 48 doses. The entire treatment process emphasizes regularity and continuity, aiming to use the immune mechanism to clear potential micro-metastatic lesions under the premise that the tumor has been removed, thereby prolonging disease-free survival.

This drug is often used in combination with multi-drug chemotherapy such as high-dose methotrexate, cisplatin, etoposide, etc. The schedule needs to be comprehensively evaluated by clinicians to avoid overlapping medications that may lead to increased toxicity. Although the side effects of mivamutin itself are relatively mild, common discomforts include low-grade fever, chills, fatigue and other "flu-like" symptoms, which often resolve within a few hours.

Overall, mivamutide, as a new type of immune auxiliary treatment, plays a positive immunomodulatory role in the comprehensive treatment of osteosarcoma, and is especially suitable for adolescent and young patient groups.

Reference materials:https://en.wikipedia.org/wiki/Mifamurtide